palovarotene Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification (HO) and fibrodysplasia ossificans progressiva (FOP). It is a highly selective retinoic acid receptor gamma (RARγ) agonist.   Wikipedia

Chemistry

  • SMILES: CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(=O)O)c(Cn4cccn4)cc12
  • InChIKey: YTFHCXIPDIHOIA-DHZHZOJOSA-N
  • Mol. Mass: 414.55
  • ALogP: 6.15
  • ChEMBL Molecule:
    palovarotene  
More Chemistry

Pharmacology

Alternative names

clm-001 | palovarotene | r-667 | rg-667 | ro-3300074

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Bone Diseases (Phase 1)

Dry Eye Syndromes (Phase 1)

Exostoses, Multiple Hereditary (Phase 2)

Myositis Ossificans (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue